Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.60 |
| ▸ | HCN4 | Q9Y3Q4 | 7/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCL2 | P13500 | 1/20 | 0.35 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15858418 | 0.86 | BRD4 (0.64) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL18870119 | 0.86 | BRD4 (0.64) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL30285155 | 0.85 | BRD4 (0.63) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL15858417 | 0.85 | BRD4 (0.63) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL2820668 | 0.85 | BRD4 (0.63) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL2450139 | 0.85 | BRD4 (0.63) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL9029087 | 0.84 | BRD4 (0.53) | BRD4HCN4GAASMN1; SMN2MAPT | |
| SCHEMBL10976351 | 0.84 | BRD4 (0.61) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL9427558 | 0.83 | BRD4 (0.52) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL20254176 | 0.83 | BRD4 (0.68) | BRD4HCN4GAASMN1; SMN2CCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566850-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE HYDROBROMIDE SALT | RICHTER GEDEON NYRT (HU) | 2018-04-11 | — | — | EP | disclosed |
| US-8415468-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-04-09 | — | — | US | disclosed |
| EP-2202225-B1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | SERVIER LAB (FR) | 2012-10-24 | — | — | EP | disclosed |
| US-8097720-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | Les Laboratories Server (FR) | 2012-01-17 | — | — | US | disclosed |
| EP-2393784-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | Les Laboratoires Servier (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089475-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010072930-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE | LES LABORATOIRES SERVIER (FR) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202225-A1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | BRD4 4035/4885HCN4 37/4885GAA 885/4885 |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | BRD4 4035/4885HCN4 37/4885GAA 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.